01—Abstract
Summary
Summary of the 8-K filed January 13, 2025. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. furnished a press release and a J.P.
Morgan Healthcare Conference presentation with its 8-K filed January 13, 2025. The Company states that it received $500 milliona upon U.S. Food and Drug Administration approval of acoramidis, from its royalty facility. It also reports $406 million in cash as of the last quarter.
The Company describes the financial information in Item 2.02 as unaudited and preliminary, notes that the audit of its financial statements for the year ended December 31, 2024 is ongoing, and states that the audit could change this information. On the commercial side, the Company reports 430 Attruby (acoramidis) prescriptions written by 248 unique healthcare providers since FDA approval on November 22, 2024. Attruby is indicated to reduce cardiovascular death and cardiovascular-related hospitalization in adults with ATTR-CM.
The Company anticipates $105 millionb in regulatory milestones in the first half of 2025 from European Union and Japan approvals of acoramidis. The Company reports that it has fully enrolled three Phase 3 trials: FORTIFY (BBP-418 for LGMD2I/R9, 112 patients), CALIBRATE (encaleret for ADH1, 70 patients), and PROPEL 3 (infigratinib for achondroplasia, 114 participants). It expects last patient or participant last visit and topline readouts for FORTIFY and CALIBRATE, and last participant last visit for PROPEL 3, in the second half of 2025.
02—Key points
Key Highlights
- Received $500 million upon acoramidis (Attruby) FDA approval, funded from the Company's royalty facility.
- Reported $406 million in cash as of the last quarter; financial information for fiscal 2024 is unaudited, preliminary, and subject to ongoing audit.
- Attruby has 430 prescriptions written by 248 unique healthcare providers since FDA approval on November 22, 2024.
- Anticipates $105 million in regulatory milestones in the first half of 2025 from acoramidis approvals in Europe and Japan.
- Completed enrollment in three major market Phase 3 trials: FORTIFY (112 patients), CALIBRATE (70 patients), and PROPEL 3 (114 participants).
- Expects topline readouts for FORTIFY (BBP-418) and CALIBRATE (encaleret), and last participant last visit for PROPEL 3 (infigratinib), in the second half of 2025.
- Presented a business update at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, with slides furnished as Exhibit 99.2.
03—Questions
Frequently Asked Questions
How much did BridgeBio receive from the acoramidis FDA approval?
The Company states that it received $500 million upon acoramidis FDA approval from its royalty facility.
How is Attruby performing commercially so far?
The Company reports 430 Attruby prescriptions written by 248 unique healthcare providers since FDA approval on November 22, 2024, with broad uptake across academic and community centers in all patient types.
What regulatory milestone payments does the Company expect in 2025?
The Company anticipates $105 million in regulatory milestones in the first half of 2025 from acoramidis approvals in the European Union and Japan.
Are the financial figures in this filing final?
No. The Company states that the Item 2.02 information is unaudited and preliminary, that the audit of its fiscal 2024 financial statements is ongoing, and that the audit could result in changes.
When are the next key pipeline readouts expected?
The Company expects last patient or participant last visit and topline readouts for FORTIFY (BBP-418) and CALIBRATE (encaleret), and last participant last visit for PROPEL 3 (infigratinib), in the second half of 2025.
04—Continue